TLR8 and head and neck squamous cell carcinoma: Recently, motolimod (VTX-2337), a selective synthetic TLR8 agonist, has been tested as adjuvant therapy in combination with chemotherapy in HNSCC patients, showing promising results, particularly in human papillomavirus (HPV) positive patients (11).